1,778 views
Epilepsy is a common neurological condition in women worldwide, with an estimated prevalence of 6 85 cases per 1000 women.1 The condition presents unique management challenges in women because hormonal changes throughout a woman's life can affect seizure control, metabolism of antiepileptic drugs and vice versa.2 For example, around one-third of women with epilepsy have catamenial epilepsy, defined as seizures that occur at certain times of the menstrual cycle.3 Research into catamenial epilepsy is progressing, but definitive treatment remains elusive because results have been inconclusive. For example, in a placebo-controlled study, the proportion of women with catamenial epilepsy who reported a 50% or greater reduction in seizure frequency during a 3-month course of cyclic progesterone treatment than that reported during a 3-month baseline period was not significantly different compared with women with non-catamenial epilepsy 4